Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing the targeting of undruggable proteins for proteasomal degradation. This approach most often employs heterobifunctional degraders consisting of a protein-targeting ligand linked to an E3 ligase recruiter to ubiquitinate and mark proteins of interest for proteasomal degradation. One challenge with this approach, however, is that only few E3 ligase recruiters currently exist for targeted protein degradation applications, despite the hundreds of known E3 ligases in the human genome. Here, we utilized activity-based protein profiling (ABPP)-based covalent ligand screening approaches to identify cysteine-reactive small-molecules that react with the E3 ubiquitin ligase RNF4 and provide chemical starting points for the design of RNF4-based degraders. The hit covalent ligand from this screen reacted with either of two zinc-coordinating cysteines in the RING domain, C132 and C135, with no effect on RNF4 activity. We further optimized the potency of this hit and incorporated this potential RNF4 recruiter into a bifunctional degrader linked to JQ1, an inhibitor of the BET family of bromodomain proteins. We demonstrate that the resulting compound CCW 28-3 is capable of degrading BRD4 in a proteasome-and RNF4-dependent manner. In this study, we have shown the feasibility of using chemoproteomics-enabled covalent ligand screening platforms to expand the scope of E3 ligase recruiters that can be exploited for targeted protein degradation applications.
In search of RNF4-targeting ligands, we screened a cysteine-reactive covalent ligand library against IA-rhodamine labeling of pure human RNF4 using gel-based ABPP (Fig. 1B; Table S1 ). We identified several potential hits from this screen, including TRH 1-74, YP 1-44, DKM 2-76, TRH 1-23, and TRH 1-163. From these, YP 1-44, TRH 1-163, and TRH 1-23 showed reproducible and dose-responsive inhibition of IArhodamine labeling of RNF4 (Fig. 1D, Fig. S1 ). Based on corresponding silver staining of RNF4 in these experiments, we found that TRH 1-163 may be causing protein precipitation. Based on gel-based ABPP analysis of general cysteine-reactivity in 231MFP lysates, YP 1-44 was much less selective compared to TRH 1-23 (Fig. S1) . Thus, TRH 1-23 appeared to be the most promising RNF4 hit (Fig. 1D) .
We next sought to identify the site-of-modification of TRH 1-23 within RNF4. We performed liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of tryptic digests from TRH 1-23-treated purified RNF4 protein and found that TRH 1-23 covalently modified either, but not both, of the two zinccoordinating cysteines C132 and C135 in the RING domain of RNF4 ( Fig. 2A, 2B) . In support of its utility as a functional RNF4 recruiter, we wanted to see if TRH 1-23 had any effect upon RNF4 autoubiquitination activity, since previous studies had shown that mutation of both cysteines to serines inhibited RNF4 function [21] [22] [23] .
Surprisingly, TRH 1-23 treatment did not inhibit RNF4 autoubiquitination activity in an in vitro reconstituted assay (Fig. 2C) .
While a promising non-functional ligand against RNF4, we considered the potency of TRH 1-23 with a 50% inhibitory concentration (IC50) in the double digit µM range in competitive ABPP suboptimal for usage as an efficient RNF4 recruiter. We thus synthesized several TRH 1-23 analogs and used gel-based ABPP to test their potency and structure-activity relationships against RNF4 (Fig. 3A) . Among these analogs, we found CCW 16, with an N-benzyl and 4-methoxyphenoxyphenyl substitution on the chloroacetamide scaffold, to be among the most potent of the analogs with inhibition of IA-rhodamine labeling of RNF4 observed down to 1 µM. Further confirmatory studies revealed the IC50 for CCW 16 to be 1.8 µM (Fig. 3B) .
To better understand how CCW 16 was interacting with RNF4, we carried out covalent docking on CCW 16 bound to either C132 or C135 on a publicly available crystal structure of RNF4 (PDB: 4PPE) (Fig.   3C ). In this model, CCW 16 covalent binding to C132 caused a small portion of the backbone to rotate flipping the C132 sidechain out into a more surface accessible conformation. The CCW 16 ligand occupied a groove on the RNF4 surface consisting of side-chains R125, T129, and S131, with no obvious polar interactions between the ligands and the protein in this model. Interestingly, CCW 16 did not occupy the zinc-binding site, left the other three zinc-coordinating cysteines (C135, C159, and C162) unperturbed (Fig. 3C) . In modeling CCW 16 covalently bound to C135, we observed a similar association with a surface groove of RNF4 occupying a region between Q161, S166, and P174. However, to accommodate the ligand, only a dihedral rotation of Ca & Cb of C132 was predicted as necessary (Fig. 3C) . Both models indicate that zinc may still be bound by the three remaining cysteines in the site, while CCW 16 binds outside of the zinc-coordinating site.
Since CCW 16 and TRH 1-23 are based on the same scaffold, these results may explain why modification by TRH 1-23 did not inhibit RNF4 autoubiquitination activity while the reported mutation of both cysteines 132 and 135 to serine leads to loss of activity.
Based on the structure-activity relationships observed with TRH 1-23 analogs, the 4-methoxy group on CCW16 presented an ideal position for extending a linker to yield a RNF4-based degrader. To demonstrate that we could use CCW 16 as a potential RNF4 recruiter for targeted protein degradation applications, we synthesized CCW 28-3, a bifunctional degrader linking CCW 16 to the BET bromodomain family inhibitor JQ1 ( Fig. 4A) 24 . CCW 28-3 was prepared in five steps from commercially available materials. Demethylation of 4-(4-methoxyphenoxy)aniline yielded 4-(4-aminophenoxy)phenol, which underwent reductive amination with benzaldehyde using sodium triacetoxyborohydride as the reducing agent to form CCW 22. Alkylation of phenolic moiety of CCW 22 with 4-(Boc-amino)butyl bromide and subsequent reaction with 2-choloracetyl chloride allowed functionalization of the RNF4 recruiter with a linker containing a "latent" reactive handle, a Boc-protected amino group. Boc deprotection by trifluoroacetic acid restored the functional primary amine which could then be reacted with a hydrolyzed free-acid form of JQ1 through amide coupling, yielding the bifunctional degrader CCW 28-3 as the final product (Supporting Methods). It is noteworthy that the amide coupling reaction should be highly versatile and thus this synthetic scheme should be applicable for conjugating different protein-targeting ligands with carboxylic acid moiety onto our RNF4 recruiter. CCW 28-3 showed higher potency for RNF4 than CCW 16 with an IC50 of 0.54 µM in the competitive ABPP assay (Fig. 4B) . Compellingly, treatment with CCW 28-3 degraded BRD4 in a dose-responsive manner in 231MFP breast cancer cells (Fig. 4C) . We also confirmed that CCW 28-3 did not inhibit RNF4 autoubiquitination activity (Fig. 4D ). CCW 28-3-mediated degradation of BRD4 was prevented by pretreatment of cells with the proteasome inhibitor bortezomib (BTZ), JQ1 alone, as well as the E1 ubiquitin activating enzyme inhibitor TAK-243 ( Fig. 4E-4F) . We next performed tandem mass tagging (TMT)-based quantitative proteomic profiling to determine the selectivity of changes in protein expression from CCW 28-3 treatment. We showed that BRD4 is one of the primary targets degraded by CCW 28-3 in 231MFP breast cancer cells ( Fig. 4G ; Table S2 ). We also observed additional downregulated targets such as MT2A, ZC2HC1A, ZNF367, and ENSA, which may represent potential off-targets of JQ1 or transcriptional or posttranslationally-driven changes in protein expression stemming from on or off-target effects of our RNF4targeting ligand in 231MFP cells. Interestingly, CCW 28-3 treatment did not lead to BRD2 and 3 degradation.
Previously reported JQ1-based degraders have shown varying levels of degradation of BET bromodomain family members with Cereblon and VHL-recruiting modules [25] [26] [27] [28] . This study highlights the utility of having additional E3 ligase recruiters for tuning the efficacy and selectivity of degraders targeting a given protein of interest.
We next used isotopic tandem orthogonal proteolysis-enabled ABPP (isoTOP-ABPP) platforms to assess the proteome-wide selectivity of CCW 28-3 4,6,7,29 ( Fig. S2 ; Table S2 ). We treated 231MFP cells with vehicle or CCW 28-3 and labeled the resulting proteomes with the cysteine-reactive N-hex-5-ynyl-2-iodoacetamide (IA-alkyne) probe, followed by appendage of isotopically light or heavy TEV protease-cleavable biotin-azide tags onto probe-labeled proteins in vehicle and CCW 28-3-treated groups, respectively. Probemodified peptides were enriched, eluted, and analyzed using previously described methods for isoTOP-ABPP 4, 6, 7, 29 . Through this analysis, we demonstrated that out of 1114 total quantified probe-modified peptides only 7 potential off-targets of CCW 28-3 showed isotopically light to heavy ratios greater than 4. This ratio >4 indicated that the covalent ligand displaced IA-alkyne probe labeling at the particular site within the protein by >75 %. Most notably, none of these off-targets of CCW 28-3 are part of the ubiquitin-proteasome system indicating that the observed BRD4 degradation can likely be attributed to RNF4-based ubiquitination ( Fig. S2 ; Table S2 ). Unfortunately, we were not able to observe the probe-modified peptide for RNF4 in this experiment likely due to its low abundance or labeling efficiency compared to other IA-alkyne labeled proteins. We were thus not able to confirm the degree of RNF4 occupancy by CCW 28-3 using isoTOP-ABPP.
We thus aimed to confirm engagement of RNF4 by CCW 28-3 in situ by other means. Since we had shown that CCW 16 was an optimized covalent ligand against RNF4, we synthesized an alkyne-functionalized derivative of CCW 16-CCW 36 (Fig. S3 ). We then overexpressed RNF4 in HEK293T cells, treated these cells with vehicle or CCW 28-3, enriched for RNF4, and then labeled the enriched RNF4 with CCW 36, followed by CuAAC-mediated appendage of rhodamine-azide to visualize CCW 36 cysteine-reactivity of RNF4 by in-gel fluorescence. Intriguingly, we only observed ~30 % engagement of RNF4 by CCW 28-3 in situ at a concentration 10-times higher than the concentration where we observed significant BRD4 degradation ( Fig.   S3 ; Fig 4C, E, F) . We attribute the low degree of target engagement to poor cell permeability of our yetunoptimized RNF4-targeting ligand. Nonetheless, our results encouragingly suggest that only a modest degree of engagement of RNF4 is sufficient to facilitate the degradation of BRD4 with CCW 28-3.
Because CCW 28-3 was not completely selective and we were targeting conserved zinc-coordinating cysteines across the RING family of E3 ligases, we next sought to confirm the contributions of RNF4 to CCW 28-3-mediated degradation of BRD4. We compared CCW 28-3-mediated BRD4 degradation in wild-type (WT) and RNF4 knockout (KO) HeLa cells. Convincingly, CCW 28-3-mediated degradation of BRD4 observed in HeLa WT cells was not evident in RNF4 KO cells ( Fig. 4H; Fig. S4 ). These data further support our claim that CCW 28-3 degrades BRD4 specifically through RNF4 recruitment.
In conclusion, our study demonstrates the feasibility of using ABPP-based covalent ligand screening in vitro to rapidly discover chemical entry points for targeting E3 ligases and that these covalent ligand hits can be identified, optimized, and incorporated into degraders for targeted protein degradation applications. While CCW 16 and CCW 28-3 are not yet completely selective for RNF4 and can only achieve fractional target engagement in cells, we demonstrate that we can still degrade BRD4 in a RNF4-dependent manner. We note that CCW 28-3 does not degrade BRD4 as well as other previously reported BRD4 degraders such as MZ1 that utilizes a VHL-recruiter linked to JQ1 25 . Future medicinal chemistry efforts can be employed to optimize the potency, selectivity, and cell permeability of CCW 16 for targeting RNF4 and to improve linker positioning and composition of CCW 28-3 to promote better degradation of protein substrates. Nonetheless, CCW 16 represents a novel, small-molecule E3 ligase recruiter for RNF4, beyond the four other E3 ligase recruiters that have been reported previously, targeting cereblon, VHL, MDM2, and cIAP 2 . Beyond RNF4, our study also highlights zinc-coordinating cysteines as a potential ligandable modality that can be targeted with cysteinetargeting covalent ligands. We believe that the approaches described here, and insights gained in this study can be utilized for future applications in expanding the scope of E3 ligase recruiters or modulators.
Methods

Covalent Ligand Library used in Initial Screen
The synthesis and characterization of many of the covalent ligands screened against RNF4 have been previously reported [4] [5] [6] 13 . Synthesis of TRH 1-156, TRH 1-160, TRH 1-167, YP 1-16, YP 1-22, YP 1-26, YP 1-31, YP 1-44 have been previously reported [30] [31] [32] [33] [34] [35] [36] [37] . The synthesis and characterization of covalent ligands that have not been reported are described in Supporting Information.
Gel-Based ABPP
Gel-based ABPP methods were performed as previously described 5, 6, 38, 39 . Pure recombinant human RNF4 was purchased from Boston Biochem (K-220). RNF4 (0.25 µg) was diluted into 50 µL of PBS and 1µL of either DMSO (vehicle) or covalently acting small molecule to achieve the desired concentration. After 30 minutes at room temperature, the samples were treated with 250 nM IA-Rhodamine (Setareh Biotech, 6222, prepared in anhydrous DMSO) for 1 h at room temperature. Samples were then diluted with 20 μL of 4x reducing Laemmli SDS sample loading buffer (Alfa Aesar) and heated at 90 °C for 5 min. The samples were separated on precast 4-20% Criterion TGX gels (Bio-Rad Laboratories, Inc.). Fluorescent imaging was performed on a ChemiDoc MP (Bio-Rad Laboratories, Inc) inhibition of target labeling was assessed by densitometry using ImageJ.
LC-MS/MS analysis of RNF4
Purified RNF4 (10 μg) was diluted into 80 µL of PBS and treated for 30 min with DMSO or compound (50 µM).
The DMSO control was then treated with light iodoacetamide (IA) while the compound treated sample was incubated with heavy IA for 1 h each at room temperature (100 μM, Sigma-Aldrich, 721328). 
RNF4 ubiquitination assay
For in vitro auto-ubiquitination assay, 200 nM RNF4 in 15 µL ubiquitination assay buffer (50 mM Tris, 150mM NaCl, 5 mM MgCl2, 5mM DTT, pH 7.4) was pre-incubated with DMSO vehicle or the covalently-acting compound for 30 min at room temperature. Subsequently, UBE1 (50 nM, Boston Biochem, E-305), UBE2D1 (400nM Boston Bichem, E2-615), Flag-ubiquitin (4000 nM, Boston Biochem, U-120) and ATP (200 µM) were added in ubiquitination assay buffer bring the total volume to 30 µL. The mixture was incubated at RT for 30 min before quenching with 10 μL of 4x Laemmli's buffer. Ubiquitination activity was measured by separation on an SDS-PAGE gel and western blotting as previously described.
Synthetic Methods and Characterization of Covalent Ligand Analogs and CCW 28-3 Degrader
Synthetic methods and characterization are detailed in Supporting Information
Covalent Docking of CCW 16 in RNF4
For covalent docking, a crystal structure of human RNF4 (PDB code: 4PPE) was used 40 . This crystal structure was then prepared for docking utilizing Schrödinger's Maestro (2018-1) protein preparation 41 .
Missing loops and side chains were added using PRIME and only A chain was utilized for docking purposes.
Protonation was carried out to optimize H-bond assignments (assuming pH 7.0) and all waters were removed.
A restrained minimization (<0.3Å) was then carried out to optimize the protein. A Zn coordinated by C132, C135, C159 & C162 was removed for docking purposes.
Prior to docking, CCW16 was prepared via LigPrep. To carry out covalent docking using Schrödinger's covalent docking 42 , either C132 or C135 were defined as the center of the binding grid (within 20A). CCW 16 was selected as the ligand and the appropriate reactive residues were selected. A "nucleophilic substitution" was selected as the reaction type and calculations were carried out on a Linux workstation with Intel Xeon 2.4GHz processors running Red Hat 6.8 with 128GB memory.
Cell Culture
The 231MFP cells were obtained from Prof. Benjamin Cravatt and were generated from explanted tumor xenografts of MDA-MB-231 cells as previously described 43 . RNF4 knockout HeLa cells were purchased from EdiGene USA (CL0033025003A). RNF4 wild-type HeLa cells were provided by EdiGene USA or the UC Berkeley Cell Culture Facility. 231MFP cells were cultured in L-15 media (Corning) containing 10% (v/v) fetal bovine serum (FBS) and maintained at 37°C with 0% CO2. HeLa cells were cultured in DMEM media (Corning) containing 10% (v/v) fetal bovine serum (FBS) and maintained at 37°C with 5% CO2.
Cell based degrader assays
For assaying degrader activity, cells were seeded (500,000 for 231MFP cells, 300,000 for HeLa cells) into a 6 cm tissue culture dish (Corning) in 2.0 -2.5 mL of media and allowed to adhere overnight. The following morning, media was replaced with complete media containing the desired concentration of compound diluted from a 1000x stock in DMSO. At the specified timepoint, cells were washed once with PBS on ice, before 150uL of lysis buffer was added to the plate (10 mM sodium phosphate, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X100). The cells were incubated in lysis buffer for 5 min before scraping and transfer to microcentrifuge tubes. The lysates were then frozen at -80C or immediately processed for western blotting. To prepare for western blotting, the lysates were cleared with 20,000 g spin for 10 min and the resulting supernatants quantified via BCA assay. The lysates were normalized by dilution with PBS to match the lowest concentration lysate and appropriate amount of 4x Laemmli's reducing buffer added.
Western blotting
Antibodies to RNF4 (Proteintech, 17810-1-AP, 1:1000), GAPDH (Proteintech, 60004-1-IG, 1:5000), BRD4 (Abcam, Ab128874, 1:1000), and beta-actin (Proteintech Group Inc., 6609-1-IG, 1:7000) were obtained from the specified commercial sources and dilutions were prepared in 5% BSA/TBST at the specified dilutions.
Proteins were resolved by SDS/PAGE and transferred to nitrocellulose membranes using the iBlot system (Invitrogen). Blots were blocked with 5 % BSA in Tris-buffered saline containing Tween 20 (TBST) solution for 1 h at room temperature, washed in TBST, and probed with primary antibody diluted in recommended diluent per manufacturer overnight at 4 °C. Following washes with TBST, the blots were incubated in the dark with secondary antibodies purchased from Ly-Cor and used at 1:10,000 dilution in 5 % BSA in TBST at room temperature. Blots were visualized using an Odyssey Li-Cor scanner after additional washes. If additional primary antibody incubations were required the membrane was stripped using ReBlot Plus Strong Antibody Stripping Solution (EMD Millipore, 2504), washed and blocked again before being re-incubated with primary antibody.
IsoTOP-ABPP chemoproteomic studies
IsoTOP-ABPP studies were done as previously reported 4, 6, 7, 29 . Briefly, cells were lysed by probe sonication in PBS and protein concentrations were measured by BCA assay 44 Beads were washed three times each in PBS and water, washed in TEV buffer solution (water, TEV buffer, 100 μM dithiothreitol) and resuspended in buffer with Ac-TEV protease (Invitrogen) and incubated overnight.
Peptides were diluted in water and acidified with formic acid (1.2 M, Spectrum) and prepared for analysis.
IsoTOP-ABPP Mass Spectrometry Analysis
Peptides from all chemoproteomic experiments were pressure-loaded onto a 250 μm inner diameter fused silica capillary tubing packed with 4 cm of Aqua C18 reverse-phase resin (Phenomenex # 04A-4299) which was previously equilibrated on an Agilent 600 series HPLC using gradient from 100% buffer A to 100% buffer B over 10 min, followed by a 5 min wash with 100% buffer B and a 5 min wash with 100% buffer A. The samples were then attached using a MicroTee PEEK 360 μm fitting (Thermo Fisher Scientific #p-888) to a 13 cm laser pulled column packed with 10 cm Aqua C18 reverse-phase resin and 3 cm of strong-cation exchange resin for isoTOP-ABPP studies. Samples were analyzed using an Q Exactive Plus mass spectrometer (Thermo (Integrated Proteomics Applications, Inc) 45 . Cysteine residues were searched with a static modification for carboxyaminomethylation (+57.02146) and up to three differential modifications for methionine oxidation and either the light or heavy TEV tags (+464.28596 or +470.29977, respectively). Peptides were required to have at least one tryptic end and to contain the TEV modification. ProLUCID data was filtered through DTASelect to achieve a peptide false-positive rate below 5%. Only those probe-modified peptides that were evident across all two out of three biological replicates were interpreted for their isotopic light to heavy ratios. Those probemodified peptides that showed ratios >3 were further analyzed as potential targets of the covalently-acting small-molecule. For modified peptides with ratios >3, we filtered these hits for peptides were present in all three biological replicates. For those probe-modified peptide ratios >3, only those peptides with 3 ratios >3 were interpreted, and otherwise replaced with the lowest ratio. For those probe-modified peptide ratios >4, only those peptides with 3 ratios >4 were interpreted, and otherwise replaced with the lowest ratio. MS1 peak shapes of any resulting probe-modified peptides with ratios >3 were then manually confirmed to be of good quality for interpreted peptides across all biological replicates.
Vectors for RNF4 Overexpression
The pCMV6-Entry-RNF4 (C-term FLAG + Myc tag) vector was purchased from Origene (RC207273). The corresponding pCMV6-Entry-eGFP vector was constructed via Gibson Assembly with primers:
GATCTGCCGCCGCGATCGCCatggtgagcaagggcgag, TCGAGCGGCCGCGTACGCGTcttgtacagctcgtccatgcc to amplify the eGFP ORF with desired overlaps, and ACGCGTACGCGGCCG, GGCGATCGCGGCGG to linearize the pCMV6-Entry backbone. Reporter ion ratio calculations were performed using summed abundances with most confident centroid selected from 20 ppm window. Only peptide-to-spectrum matches that are unique assignments to a given identified protein within the total dataset are considered for protein quantitation. High confidence protein identifications were reported using a Percolator estimated <1% false discovery rate (FDR) cut-off. Differential abundance significance was estimated using a background-based ANOVA with Benjamini-Hochberg correction to determine adjusted p-values. Table   S2 for details. - RNF4 C132   b2   y2   b3 b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15  b17 b18 b19  b21 b22  b24   y3  y4  y5  y6  y7  y8  y9  y10  y11  y12  y13  y14  y15  y16  y17  y18  y22  y23  y24  y25  y26  y28   b26   250  500  750  1000  1250  1500  1750  2000  2250  0   22 
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